Repository corticotropin injection improves quality metrics in an observational study of multiple sclerosis relapse
Aim: To determine whether clinicians evaluate American Academy of Neurology (AAN) quality metrics for patients with multiple sclerosis (MS) relapse and whether repository corticotropin injection (RCI) improves clinical and patient-reported outcomes associated with these metrics at 2 and 6 months after treatment. Methods: A multicenter, prospective, observational registry evaluating patients receiving RCI for MS relapse (N = 125) categorized data according to AAN quality metrics involving diagnosis, disability, fatigue, cognitive impairment, depression, and quality of life. Results: Clinicians assessed all 11 AAN quality metrics in patients with MS relapse. Disability, fatigue, cognitive impairment, depression, and quality of life outcomes improved with RCI therapy. Conclusion: RCI was associated with improved quality metrics, and AAN guidelines were followed during routine RCI treatment for MS relapse.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Neurodegenerative disease management - 11(2021), 6 vom: 19. Dez., Seite 469-476 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kaplan, Jeffrey [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9002-60-2 |
|---|
| Anmerkungen: |
Date Completed 30.03.2022 Date Revised 01.04.2022 published: Print-Electronic ClinicalTrials.gov: NCT02633033 Citation Status MEDLINE |
|---|
| doi: |
10.2217/nmt-2021-0030 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333969154 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333969154 | ||
| 003 | DE-627 | ||
| 005 | 20231226203927.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nmt-2021-0030 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1113.xml |
| 035 | |a (DE-627)NLM333969154 | ||
| 035 | |a (NLM)34860120 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kaplan, Jeffrey |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Repository corticotropin injection improves quality metrics in an observational study of multiple sclerosis relapse |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.03.2022 | ||
| 500 | |a Date Revised 01.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02633033 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: To determine whether clinicians evaluate American Academy of Neurology (AAN) quality metrics for patients with multiple sclerosis (MS) relapse and whether repository corticotropin injection (RCI) improves clinical and patient-reported outcomes associated with these metrics at 2 and 6 months after treatment. Methods: A multicenter, prospective, observational registry evaluating patients receiving RCI for MS relapse (N = 125) categorized data according to AAN quality metrics involving diagnosis, disability, fatigue, cognitive impairment, depression, and quality of life. Results: Clinicians assessed all 11 AAN quality metrics in patients with MS relapse. Disability, fatigue, cognitive impairment, depression, and quality of life outcomes improved with RCI therapy. Conclusion: RCI was associated with improved quality metrics, and AAN guidelines were followed during routine RCI treatment for MS relapse | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a AAN quality metrics | |
| 650 | 4 | |a Acthar Gel | |
| 650 | 4 | |a multiple sclerosis | |
| 650 | 4 | |a relapsing-remitting | |
| 650 | 4 | |a repository corticotropin injection | |
| 650 | 7 | |a Adrenocorticotropic Hormone |2 NLM | |
| 650 | 7 | |a 9002-60-2 |2 NLM | |
| 700 | 1 | |a Miller, Tamara |e verfasserin |4 aut | |
| 700 | 1 | |a Baker, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Due, Bryan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Enxu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurodegenerative disease management |d 2011 |g 11(2021), 6 vom: 19. Dez., Seite 469-476 |w (DE-627)NLM217401074 |x 1758-2032 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:6 |g day:19 |g month:12 |g pages:469-476 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/nmt-2021-0030 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 6 |b 19 |c 12 |h 469-476 | ||